BOUNDLESS BIO INC
BOLDNASDAQTrading Snapshot
- Day Range
- $2.55 – $2.61
- 52-Week Range
- $0.96 – $3.16
- Volume
- $4.34B
- Avg Volume
- $3.57B
- Shares Outstanding
- 22.5M
- Next Earnings
- Nov 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $3M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.86
- Dividend Yield
- —
- Dilution (1yr)
- +31.7%
Why Investors Own BOLD
- ✓High-growth profile — revenue up +4.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BOUNDLESS BIO INC
BOLD
StockOtter · stockotter.spaceAbout BOUNDLESS BIO INC
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer and Shiva G. Fritsch a
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and conti
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.